FLC Capital Advisors Has $438,000 Stake in Abbott Laboratories (NYSE:ABT)

FLC Capital Advisors trimmed its stake in Abbott Laboratories (NYSE:ABT) by 8.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,983 shares of the healthcare product maker’s stock after selling 356 shares during the period. FLC Capital Advisors’ holdings in Abbott Laboratories were worth $438,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Patriot Investment Management Group Inc. lifted its position in Abbott Laboratories by 3.1% during the fourth quarter. Patriot Investment Management Group Inc. now owns 3,236 shares of the healthcare product maker’s stock valued at $356,000 after purchasing an additional 96 shares during the period. Shepherd Financial Partners LLC lifted its position in Abbott Laboratories by 4.5% during the fourth quarter. Shepherd Financial Partners LLC now owns 2,275 shares of the healthcare product maker’s stock valued at $250,000 after purchasing an additional 99 shares during the period. Stonebridge Capital Advisors LLC lifted its position in Abbott Laboratories by 0.5% during the first quarter. Stonebridge Capital Advisors LLC now owns 20,029 shares of the healthcare product maker’s stock valued at $2,371,000 after purchasing an additional 100 shares during the period. Landaas & Co. WI ADV lifted its position in Abbott Laboratories by 1.8% during the fourth quarter. Landaas & Co. WI ADV now owns 5,534 shares of the healthcare product maker’s stock valued at $608,000 after purchasing an additional 100 shares during the period. Finally, Renaissance Investment Group LLC raised its position in Abbott Laboratories by 0.7% in the fourth quarter. Renaissance Investment Group LLC now owns 14,204 shares of the healthcare product maker’s stock worth $1,563,000 after acquiring an additional 100 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.8 %

Shares of ABT stock traded up $1.97 during trading hours on Wednesday, reaching $113.47. 7,532,730 shares of the stock were exchanged, compared to its average volume of 5,754,951. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The company’s 50-day moving average price is $115.14 and its 200-day moving average price is $106.37. The firm has a market capitalization of $196.89 billion, a price-to-earnings ratio of 34.84, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.19. The company had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.03 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be given a $0.55 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 annualized dividend and a dividend yield of 1.94%. Abbott Laboratories’s payout ratio is presently 67.48%.

Insider Transactions at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,435 shares of company stock valued at $6,451,298. Company insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of several recent research reports. Citigroup increased their price target on shares of Abbott Laboratories from $123.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 13th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Barclays increased their price objective on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Finally, Raymond James increased their price objective on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.